Search

Your search keyword '"Casadio, V."' showing total 131 results
Start Over Author "Casadio, V."
131 results on '"Casadio, V."'

3. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Author

Vincenza Conteduca, Jayaram, A., Romero-Laorden, N., Wetterskog, D., Salvi, S., Gurioli, G., Scarpi, E., Castro, E., Marin-Aguilera, M., Lolli, C., Schepisi, G., Maugeri, A., Wingate, A., Farolfi, A., Casadio, V., Medina, A., Puente, J., Vidal, Mjm, Morales-Barrera, R., Villa-Guzmán, Jc, Hernando, S., Rodriguez-Vida, A., González-Del-Alba, A., Mellado, B., Gonzalez-Billalabeitia, E., Olmos, D., Attard, G., and Giorgi, U.

Subjects
Male, Time Factors, antagonistas de andrógenos, humanos, calicreínas, androstenos, Antineoplastic Agents, Docetaxel, Article, Androgen receptor-directed therapies, factores de tiempo, antígeno prostático específico, Androgen receptor–directed therapies, Nitriles, Phenylthiohydantoin, Antineoplastic Combined Chemotherapy Protocols, Humans, antineoplásicos, Neoplasm Metastasis, metástasis neoplásica, Castration-resistant prostate cancer, protocolos de quimioterapia antineoplásica combinada, Prostatic Neoplasms, Androgen Antagonists, Biomarker, Prostate-Specific Antigen, Progression-Free Survival, feniltiohidantoína, Prostatic Neoplasms, Castration-Resistant, Androgen receptor, Plasma DNA, Receptors, Androgen, Spain, Benzamides, neoplasias de la próstata, Androstenes, Kallikreins
Abstract

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR] = 1.61, 95% confidence interval [CI] = 1.08-2.39, p = 0.018), but not PFS (HR = 1.04, 95% CI 0.74-1.46, p = 0.8) or PSA response (odds ratio = 1.14, 95% CI = 0.65-1.99, p = 0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naive, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR = 0.16, 95% CI = 0.06-0.46, p < 0.001) and PFS (HR = 0.31, 95% CI = 0.12-0.80, p = 0.02). Specifically, we reported a significant difference for OS favoring abiraterone/enzalutamide for AR-normal patients (HR = 1.93, 95% CI = 1.19-3.12, p = 0.008) and a suggestion favoring docetaxel for AR-gained patients (HR = 0.53, 95% CI = 0.24-1.16, p = 0.11). These data suggest that AR-normal patients should receive abiraterone/enzalutamide and AR-gained could benefit from docetaxel. This treatment selection merits prospective evaluation in a randomized trial. Patient summary: We investigated whether plasma androgen receptor (AR) predicted outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel, and we performed an exploratory analysis in patients treated with docetaxel or AR-directed drugs as first-line mCRPC therapy. We showed that plasma AR normal favored hormonal treatment, whilst plasma AR-gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker., V. Conteduca was funded by a European Society of Medical Oncology Translational Clinical Research Fellowship. A. Jayaram is supported by a grant from the Medical Research Council (MR/P002072/1). G. Attard is supported by a Cancer Research UK Advanced Clinician Scientist Grant (A22744). This work was funded in part by Prostate Cancer UK (PG12-49), the Instituto de Salud Carlos III (ISCII) PI16/01565 grant E. Gonzalez-Billalabeitia was funded by a grant from the Instituto de Salud Carlos III (ISCIII) PI15/01499. N. Romero-Laorden was funded by a grant from the Instituto de Salud Carlos III (CM14-00200). E. Castro is supported by a Prostate Cancer Foundation Young Investigator Award (2017). E. Castro and D. Olmos are supported by grants from the Ministerio de Economia, Industria y Competitividad (JCI-2014-19129 to E.C., RYC-2015-18625 to D.O.). B. Mellado and M. Marin-Aguilera work were supported by the Instituto de Salud Carlos III-Subdireccion General de Evaluacion y Fomento de la Investigacion (PI12/01226 and PI15/676) and co-funded by the European Regional Development Fund. Funding from CERCA Programme/Generalitat de Catalunya is gratefully acknowledged. During the conduct of the study, E. Castro was supported by a grant from the Ministerio de Educacion, Cultura y Deportes (CAS17/00182). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all data and had the final responsibility for the decision to submit for publication.

Published
2019

7. Ecuba da Omero all’Ecuba di Euripide

Author

Casadio, V

Subjects
Ecuba, Omero, Epica, Euripide, Tragedia greca, Letteratura greca, Hecuba, Homer, Epos, Greek Tragedy, Ancient Greek Literature, Settore L-FIL-LET/02 - Lingua e Letteratura Greca
Published
2018

8. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Author

Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, Enrique, Fernández-Pérez, M. P., Jayaram, A., Castellano-Castillo, Daniel, Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vázquez-Estévez, S., González del Alba, Aránzazu, Mellado, B., Fernández-Calvo, O., Méndez-Vidal, M. J., Climent, M. A., Durán, Ignacio, Gallardo, Eduard, Rodríguez, A., Santander, C., Sáez, María Isabel, Puente, Javier, Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., de Giorgi, U., González-Billalabeitia, E., Attard, G., Prostate Cancer UK, Cancer Research UK, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research (UK), European Society for Medical Oncology, Health Research Board (Ireland), Medical Research Council (UK), European Commission, Instituto de Salud Carlos III, Sociedad Española de Oncología Médica, Chris Foundation, and Spanish Oncology Genitourinary Group

Subjects
Androgen receptor, Plasma DNA, Enzalutamide, urologic and male genital diseases, Abiraterone, Biomarkers, Castration-resistant prostate cancer
Abstract

[Background] There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC., [Methods] We optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial)., [Results] In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74–9.10; P A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47–not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94–9.68; P, [Conclusion] Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required., [Clinical Trial number] NCT02288936 (PREMIERE trial)., This work was funded by Prostate Cancer UK (PG12-49) and Cancer Research UK (A13239) and was supported by the NIHR Royal Marsden and the Institute of Cancer Research (ICR) Biomedical Research Centre. VC was funded by a European Society of Medical Oncology Translational Clinical Research Fellowship, AJ by an Irish Health Research Board Clinical Research Fellowship and a Medical Research Council Clinical Research Fellowship, DGT by a European Union Marie Curie Intra-European Postdoctoral Fellowship, EG by Instituto de Salud Carlos III and the Spanish Society of Medical Oncology (SEOM)/Chris Foundation (no grant numbers apply) and GA by a Cancer Research UK Advanced Clinician Scientist Fellowship. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The PREMIERE trial was sponsored by Spanish Genito-Urinary oncology Group that received a grant from Astellas to support the conduct of the trial.

Published
2017

9. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Author

Conteduca, V, Wetterskog, D, Sharabiani, M. T. A, Grande, Elisabetta, Fernandez Perez, M. P, Jayaram, A, Salvi, S, Castellano, D, Romanel, Alessandro, Lolli, C, Casadio, V, Gurioli, G, Amadori, D, Font, A, Vazquez Estevez, S, González Del Alba, A, Mellado, B, Fernandez Calvo, O, Méndez Vidal, M. J, Climent, M. A, Duran, I, Gallardo, E, Rodriguez, A, Santander, C, Sáez, M. I, Puente, J, Gasi Tandefelt, D, Wingate, A, Dearnaley, D, Demichelis, Francesca, De Giorgi, U, Gonzalez Billalabeitia, E, and Attard, G.

Subjects
Adult, Male, Time Factors, plasma DNA, Antineoplastic Agents, Hormonal, DNA Mutational Analysis, Kaplan-Meier Estimate, urologic and male genital diseases, Disease-Free Survival, Circulating Tumor DNA, abiraterone, androgen receptor, biomarker, castration-resistant prostate cancer, enzalutamide, Predictive Value of Tests, Risk Factors, Nitriles, Phenylthiohydantoin, Biomarkers, Tumor, Odds Ratio, Humans, 1112 Oncology and Carcinogenesis, Prospective Studies, Oncology & Carcinogenesis, Precision Medicine, Aged, Proportional Hazards Models, Aged, 80 and over, Patient Selection, Middle Aged, Europe, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Receptors, Androgen, Benzamides, Multivariate Analysis, Mutation, Disease Progression, Androstenes, Multiplex Polymerase Chain Reaction
Abstract

Background There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. Methods We optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial). Results In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74–9.10; P A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47–not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94–9.68; P

Published
2017

10. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Author

Prostate Cancer UK, Cancer Research UK, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research (UK), European Society for Medical Oncology, Health Research Board (Ireland), Medical Research Council (UK), European Commission, Instituto de Salud Carlos III, Sociedad Española de Oncología Médica, Chris Foundation, Spanish Oncology Genitourinary Group, Conteduca, V., Wetterskog, D., Sharabiani, Mansour T. A., Grande, Enrique, Fernández-Pérez, M. P., Jayaram, A., Castellano-Castillo, Daniel, Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vázquez-Estévez, Sergio, González del Alba, Aránzazu, Mellado González, Begoña, Fernández-Calvo, Ovidio, Méndez-Vidal, M. J., Climent, Miguel A., Durán, Ignacio, Gallardo, Eduard, Rodríguez, A., Santander, Carmen, Sáez, María Isabel, Puente Vázquez, Javier, Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., de Giorgi, U., González-Billalabeitia, E., Attard, G., Prostate Cancer UK, Cancer Research UK, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research (UK), European Society for Medical Oncology, Health Research Board (Ireland), Medical Research Council (UK), European Commission, Instituto de Salud Carlos III, Sociedad Española de Oncología Médica, Chris Foundation, Spanish Oncology Genitourinary Group, Conteduca, V., Wetterskog, D., Sharabiani, Mansour T. A., Grande, Enrique, Fernández-Pérez, M. P., Jayaram, A., Castellano-Castillo, Daniel, Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vázquez-Estévez, Sergio, González del Alba, Aránzazu, Mellado González, Begoña, Fernández-Calvo, Ovidio, Méndez-Vidal, M. J., Climent, Miguel A., Durán, Ignacio, Gallardo, Eduard, Rodríguez, A., Santander, Carmen, Sáez, María Isabel, Puente Vázquez, Javier, Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., de Giorgi, U., González-Billalabeitia, E., and Attard, G.

Abstract

[Background] There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC., [Methods] We optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial)., [Results] In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74–9.10; P < 0.001 and HR 3.81; 95% CI 2.28–6.37; P < 0.001, respectively], PFS (HR 2.18; 95% CI 1.08–4.39; P = 0.03, and HR 1.95; 95% CI 1.23–3.11; P = 0.01, respectively) and rate of PSA decline ≥50% [odds ratio (OR), 4.7; 95% CI 1.17–19.17; P = 0.035 and OR, 5.0; 95% CI 1.70–14.91; P = 0.003, respectively]. AR mutations [2105T>A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47–not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94–9.68; P < 0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26–19.93; P < 0.001) and OS (HR 11.08; 95% CI 2.16–56.95; P = 0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts., [Conclusion] Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required., [Clinical Trial number] NCT02288936 (PREMIERE trial).

Published
2017

11. L’Inaco e Argo nell'epos arcaico

Author

Casadio, V

Subjects
Filologia Classica, Classical Philology, Ancient Greek Epic, Ancient Greek Literature, Ancient Greek Histoy, Ancient Greek Lexicography, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, Letteratura greca, Settore L-FIL-LET/05 - Filologia Classica, Settore L-ANT/02 - Storia Greca, Storia Greca, Epica greca arcaica
Published
2016

12. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer

Author

Conteduca, V., primary, Scarpi, E., additional, Caroli, P., additional, Salvi, S., additional, Lolli, C., additional, Burgio, S. L., additional, Menna, C., additional, Schepisi, G., additional, Testoni, S., additional, Gurioli, G., additional, Paganelli, G., additional, Casadio, V., additional, Matteucci, F., additional, and De Giorgi, U., additional

Published
2017
Full Text
View/download PDF

13. Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC)

Author

Conteduca, V., primary, Salvi, S., additional, Caroli, P., additional, Scarpi, E., additional, Schepisi, G., additional, Lolli, C., additional, Wetterskog, D., additional, Burgio, S.L., additional, Menna, C., additional, Casadio, V., additional, Matteucci, F., additional, Paganelli, G., additional, Attard, G., additional, and De Giorgi, U., additional

Published
2017
Full Text
View/download PDF

15. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Author

Conteduca, V., primary, Wetterskog, D., additional, Sharabiani, M.T.A., additional, Grande, E., additional, Fernandez-Perez, M.P., additional, Jayaram, A., additional, Salvi, S., additional, Castellano, D., additional, Romanel, A., additional, Lolli, C., additional, Casadio, V., additional, Gurioli, G., additional, Amadori, D., additional, Font, A., additional, Vazquez-Estevez, S., additional, González del Alba, A., additional, Mellado, B., additional, Fernandez-Calvo, O., additional, Méndez-Vidal, M.J., additional, Climent, M.A., additional, Duran, I., additional, Gallardo, E., additional, Rodriguez, A., additional, Santander, C., additional, Sáez, M.I., additional, Puente, J., additional, Gasi Tandefelt, D., additional, Wingate, A., additional, Dearnaley, D., additional, Demichelis, F., additional, De Giorgi, U., additional, Gonzalez-Billalabeitia, E., additional, and Attard, G., additional

Published
2017
Full Text
View/download PDF

17. Increased choline uptake in androgen receptor (AR) copy number gain castration-resistant prostate cancers (CRPC)

Author

Conteduca, V., primary, Casadio, V., additional, Caroli, P., additional, Scarpi, E., additional, Lolli, C., additional, Menna, C., additional, Bianchi, E., additional, Schepisi, G., additional, Testoni, S., additional, Gurioli, G., additional, Salvi, S., additional, Amadori, D., additional, Paganelli, G., additional, Matteucci, F., additional, Attard, G., additional, and De Giorgi, U., additional

Published
2016
Full Text
View/download PDF

18. Euripide, Oreste e la 'trilogia allargata'

Author

Casadio, V

Subjects
Euripide, Trilogia, Dramma antico, Letteratura greca antica, Euripides, Trilogy, Ancient drama, Ancient Greek Literature, Settore L-FIL-LET/02 - Lingua e Letteratura Greca
Published
2013

19. Nel segno di Cadmo.Personaggi e situazioni delle 'Fenicie' di Euripide

Author

Casadio, V

Subjects
Tragedy, Greek Literature, Phoenician women, Fenicie, Letteratura Greca, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, Cadmus, Phoenician women, Tragedy, Euripides, Greek Literature, Labdacidi, Euripides, Cadmo, Euripide, Cadmo, Fenicie, Labdacidi, Tragedia, Euripide, Letteratura Greca, Cadmus, Tragedia
Published
2012

20. L'ira di Augusto (Plut. Mor. 194a-208a)

Author

Casadio, V

Subjects
History, Augusto, Literature, Storia, Plutarco, Augusto, Plutarco, Ira, Storia, Letteratura, Letteratura, Augustus, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, Anger, Ira, Augustus, Plutarch, Anger, History, Literature, Plutarch
Published
2012

23. 2577 The correlation between circulating cell-free AR and CYP17A1 copy number variations and tumor burden estimated by 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Author

Conteduca, V., primary, Salvi, S., additional, Caroli, P., additional, Scarpi, E., additional, Lolli, C., additional, Burgio, S.L., additional, Menna, C., additional, Schepisi, G., additional, Bianchi, E., additional, Gurioli, G., additional, Paganelli, G., additional, Casadio, V., additional, Matteucci, F., additional, Attard, G., additional, and De Giorgi, U., additional

Published
2015
Full Text
View/download PDF

24. L'arciere nell'antichità greca e romana : Mito, letteratura e storia

Author

Casadio, V

Subjects
antichità greca, arciere, letteratura, Settore L-FIL-LET/04 - Lingua e Letteratura Latina, mito, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, antichità romana, storia, Settore L-ANT/07 - Archeologia Classica, Settore L-FIL-LET/03 - Filologia Italica, Illirica, Celtica
Published
2010

25. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone

Author

Salvi, S, primary, Casadio, V, additional, Conteduca, V, additional, Burgio, S L, additional, Menna, C, additional, Bianchi, E, additional, Rossi, L, additional, Carretta, E, additional, Masini, C, additional, Amadori, D, additional, Calistri, D, additional, Attard, G, additional, and De Giorgi, U, additional

Published
2015
Full Text
View/download PDF

27. Lexicographers, Ancient Greek

Author

Casadio, V

Subjects
Lessicoografi, Greci, antichi, Lessicoografi, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, Greci, antichi
Published
2009

28. Il nome, la veste e lo specchio della moglie di s. Alessio

Author

Lauro, R, Caputo, Lr, Salvatori, F, Lanzillotta, E, Bonanno, Mg, Finazzi Agrò, A, Chiusuri, A, Colamartino, D, Cascone, I, Agati, Ml, Braidotti, C, Carbonetti Venditelli, C, Casadio, V, Casali, S, Cerbo, E, Chiodo, Cm, Chiusaroli, F, Dettori, Dragotto, F, Falivene, Mr, Filippin, A, Foglia, F, Gemmiti, D, Giubilo, B, Lanna, S, Lucà, S, Luciani, C, Malavolta, M, Marpicati, P, Maurizio, V, Pace, C, Paoli, E, Pierangeli, F, Poccetti, P, Poznanski, Mc, Privitera, T, Scarcia, R, Signorini, M, Stok, F, Ambrogini, A, Angelelli, W, Bonanome, D, Della Giovampaola, I, Fiocchi Nicolai, V, Gallo, S, Gentilini, L, Gentilini, Md, Ghisellini, E, Montanari, T, Negri Arnoldi, F, Palma Venetucci, B, Pisani, M, Rocco, G, Romeo, I, Spera, L, Valeriani, A, Vatta, G, Antolini, S, Arnaldi, A, Brancacci, A, Chiappini, A, Costa, V, Dottori, R, Erdas, D, Von, Fv, Ferri, G, Foderà, V, Garofalo, P, Gasperini, L, Giuliani, F, Inglese, A, Nicolai, Rm, Pasqualini, A, Prosperi Valenti, G, Quadrino, D, Serafin, P, and Serra, A

Subjects
Settore L-FIL-LET/08 - Letteratura Latina Medievale e Umanistica
Published
2009

29. Oros (Gr. Ôros)

Author

Casadio, V

Subjects
greco, antico, Oro, Oro, grammatico, greco, antico, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, grammatico
Published
2009

30. Martianus (Minneus Felix) Capella

Author

Casadio, V

Subjects
Marziano. Capella,grammatico, Settore L-FIL-LET/04 - Lingua e Letteratura Latina, grammatico, Marziano. Capella
Published
2009

31. Glossography, Ancien Greek

Author

Casadio, V

Subjects
greca, antica, glossografia, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, glossografia, greca, antica
Published
2009

32. Apion

Author

Casadio, V

Subjects
Apione, grammatico, Apione, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, grammatico
Published
2009

33. Etymology, Ancien Greek

Author

Casadio, V

Subjects
greca, Etimologia, Etimologia, greca, antica, antica, Settore L-FIL-LET/02 - Lingua e Letteratura Greca
Published
2009

40. Hesych. π 4496 Hansen

Author

Casadio, V

Subjects
Esichio, Sparta, frammento, poetico, Sparta, poetico, frammento, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, Esichio
Published
2005

42. Suggestioni saffiche in Posidipp. Ep. 55 A.-B

Author

Casadio, V

Subjects
Posidippus, Ancient Greek Literature, Posidippus, Sappho, Saffo, Letteratura greca,Posidippo,Saffo, Posidippo, Ancient Greek Literature, Settore L-FIL-LET/02 - Lingua e Letteratura Greca, Sappho, Letteratura greca
Published
2005

46. Ar and Cyp17A1 Copy Number Variations May Predict Clinical Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone

Author

Conteduca, V., primary, Salvi, S., additional, Casadio, V., additional, Burgio, S.L., additional, Menna, C., additional, Rossi, L., additional, Bianchi, E., additional, Carretta, E., additional, Fabbri, F., additional, Callistri, D., additional, Zoli, W., additional, and De Giorgi, U., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results